Introduction: Somatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs.
Aim(s): To evaluate gallstone disease incidence and associated factors in a series of patients treated with long-acting somatostatin analogs for neuroendocrine neoplasms.
Materials and methods: A prospectively-collected database of patients with a diagnosis of neuroendocrine neoplasms, treated with somatostatin analogs at our Institution between 2010 and 2018, was retrospectively analyzed. Patients’ demographics and disease characteristics were analyzed to evaluate the incidence and the factors related to biliary stone disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Zhirong Qi
To read results and conclusion, please login ...
Further abstracts you may be interested in